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Genomic	arrays	are	based	on	the	large	scale	analy­
sis	of	the	genome	information	to	predict	prognosis,	for	
a	better	management	of	 the	disease	and	to	 identify	
molecular	targets	in	order	to	discover	new	drugs.
Cancer	is	the	result	of	a	multistep	process	of	mu­
tations	in	key	regulatory	genes	and	epigenetic	altera­
tions	that	result	in	loss	of	balanced	gene	expression.	
A	complete	knowledge	of	the	interaction	between	the	
genetic	variability	of	 the	neoformation	 (tumor	profi­
ling)	and	the	genetic	variability	of	the	host	(inherited	
genome	profiling),	will	be	able	to	determine	the	better	
strategy	against	 the	cancer	and	 the	 less	 toxicity	 for	
the	patient.
TUMOR PROFILING
Many	 tumors	 harbor	 somatic	mutations	which	
make	them	resistant	to	therapy.	For	example:	paradox	
prostate	cancer	 responses	 to	antiadrogens	or	glu­
cocorticoids	in	the	“androgen	withdrawal	syndrome”	
have	been	 related	 to	pharmacogenetic	alterations	
in	 the	sequence	of	 the	hormone	binding	domain	of	
the	androgen	receptor;	mutations	in	the	tubulin	gene	
determine	 resistance	 to	 chemotherapeutic	 drugs	
such	as	vinblastin,	etoposide	or	taxanes.	Radioresis­
tance	has	been	associated	with	overexpression	of	the	
EGR­1	gene	[1].	Moreover,	the	status	of	the	target	in	
the	neoplastic	mechanism	 is	particularly	 important	
for	 new	 therapies	using	 receptor	 ligands	 such	as	
endothelin­1	antagonists	or	monoclonal	antibodies	
such	as	cetuximad	or	trastuzumab	which	are	directed	
against	specific	extracellular	binding	domains	of	the	
growth	factor	receptors	EGFR	(Erb	B1)	or	Her­2/Neu	
(Erb	B2),	respectively.	Other	molecular	alterations	in	
tumors	have	been	associated	with	drug	resistance	or	
sensitivity.	They	are	not	restricted	to	a	specific	drug	
because	they	 involve	 the	multidrug	resistance	gene	
family	(MDR	1)	or	ubiquitous	genes	(p53,	bcl­2,	p21,	
p14,	topoisomerases	I	and	II,	which	regulate	cell	cycle	
proliferation),	apoptosis	or	DNA	repair	[2].	The	num­
ber	of	molecular	alterations	observed	in	tumors	and	
genetic	complexity	which	could	determine	therapeutic	
efficiency	 in	a	global	 fashion	has	suggested	using	
high­density	microrrays	 in	order	 to	generate	 tumor	
profiling	from	thousands	of	gene	patterns	[1,	2].	
HIGH-DENSITY ARRAYS
In	urologic	oncology,	the	use	of	expression	profiling	
for	diagnosis,	classification	and	outcome	prediction	
was	recently	demonstrated	using	micro	arrays	on	pro­
state	and	other	cancers	of	the	uro­genital	apparatus.	
Because	genetic	or	epigenetic	events	can	be	impor­
tant	 in	malignant	progression	or	drug	response,	the	
identification	of	large	scale	genomic	or	protein	profiling	
could	be	promising	[3].	Tumors	and	particularly	pro­
state	cancers	are	heterogeneous	mixtures	of	different	
cell	types	which	can	complicate	the	interpretation	of	
genomic	analysis	[1].	Because	of	this	heterogeneity,	
sample	 selection	 is	 an	 important	 issue	and	needs	
careful	 histopathologic	examination	of	 specimens	
before	microarrays	analysis	[3].	In	some	cases,	laser	
capture	micro	dissection	techniques	combined	with	
the	DNA,	RNA	or	protein	chip	technology	allows	for	
the	isolation	of	selected	cells	from	a	tissue	section	and	
has	been	used	to	isolate	specific	and	homogeneous	
cell	types.	Mapping	of	cancerous	foci,	blood	vessels	
or	immunocompetent	cells	in	malignant	tissues	can	be	
used	to	identify	tissue­specific	markers	that	serve	as	
potential	targets	for	in vivo	drug	delivery	[4].
However,	apart	from	the	fact	that	microdissection	
reduces	the	scope	of	dissection	of	biological	events	
in	a	single	choice	cell	 type	and	for	example	occults	
interaction	between	different	cell	 compartments	 in	
pathological	tissues,	it	is	difficult	to	obtain	adequate	
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amounts	of	high	quality	RNA	for	expression	profiling	
[2].	Microarrays	usually	require	between	10	to	40	μg	
(2	μg	at	 least	 for	 radio­labeled	nucleic	acid)	of	high	
quality	RNA,	corresponding	roughly	to	a	100	mm3		piece	
of	tissue.	To	obtain	high	quality	RNA,	tissue	samples	
should	be	snap­frozen	in	liquid	nitrogen	within	half	an	
hour	of	trans­rectal	or	trans­urethral	multiple	biopsies	
of	the	gland	and	stored	at	–80	°C.	Unfortunately,	and	
contrary	to	DNA,	methods	do	not	yet	exist	for	obtaining	
sufficient	mRNA	from	formalin­fixed	tissues	[1,	2].	
Microarray	slides	are	shared	in	two	groups	depend­
ing	on	the	type	of	nucleic	acid	spotted	onto	the	slide	
and	 the	method	used	 to	array	and	spot	 it:	 i)	micro	
arrays	manufactured	with	 in situ	 synthesized	oligo­
nucleotides	between	25	to	80	mers;	ii)	spotted	nucleic	
acids	(with	pin	tool	or	ink	jet	technology)	including	long	
oligonucleotides	(80	mers)	or	DNA	fragments	(cDNA,	
genomic	DNA).	Whereas	the	two	types	of	micro	arrays	
could	be	used	for	gene	expression,	oligonucleotide	
micro	arrays	are	usually	chosen	 for	detecting	point	
mutations,	and	DNA	 fragments	micro	arrays	could	
be	used	for	genomic	 integrity	 testing	by	decrypting	
chromosome	alterations	(comparative	genomic	hydri­
dization	array,	CGH	array)	[5].
Using	DNA	or	array	based	comparative	genomic	
hydridization	(aCGH)	in	prostate	cancer	is	able	to	finely	
map	chromosomal	deletions	 (and	amplifications)	 in	
tumors.	Using	a	CGH,	more	additional	subtle	genomic	
changes,	like	amplicons	or	homozygous	deletions,	are	
detected	 in	the	prostate	cancer	genome	than	using	
cytogenetic	or	classic	CGH	techniques	and	demon­
strate	 the	viability	of	a	CGH	 for	mapping	 regions	of	
chromosomal	aberrations	[5,	6].
aCGH	represents	an	advance	beyond	metaphase	
CGH,	and	is	a	more	sensitive,	higher	resolution	tech­
nique.	Standard	CGH	has	been	informative,	however	
the	limit	of	resolution	is	10–15	Mb,	making	fine	map­
ping	of	regions	impractical	[5].	In	aCGH,	chromosomal	
loci	with	copy	number	changes	are	linked	to	the	hu­
man	genome	sequence	by	the	genomic	coordinates	
of	BAC	clones	on	the	array,	defining	amplifications	or	
deletions	with	resolution	limited	only	by	the	spacing	
of	BAC	clines	on	 the	human	genome.	Thus	aCGH	
can	both	more	accurately	define	subtle	aberrations	
undetectable	using	standard	CGH,	and	 resolve	 the	
boundaries	of	known	regions	[3,	5].	The	data	derived	
from	aCGH	analysis	can	be	clustered,	similar	to	gene	
expression	profiling,	thus	providing	a	powerful	method	
to	cluster	tumors	[4,	5].
Different	methods	using	RNA	(cDNA)	on	array	are	
available	for	large	scale	gene	expression	analysis	[2].	
Some	of	 them	are	powerful	as	 they	are	completely	
open	systems	(no	knowing	material	 is	required)	 like	
differential	display	or	serial	analysis	of	gene	expression	
(SAGE)	but	 they	are	 technically	heavy	and	very	ex­
pensive	[3,	5].	Microarray	techniques	belong	to	semi­
closed	systems,	because	sequences	of	immobilized	
nucleic	acids	should	be	known.	This	technology	came	
to	light	almost	ten	years	ago	with	the	first	addressable	
in vitro	synthesis	of	oligonucleotides	onto	a	solid	sur­
face	leading	to	the	first	application	in	discriminating	
human	pathologies	based	on	the	expression	of	sets	
of	genes	[7].
Microarray	experiments	generate	 thousands	of	
data	which	need	organization,	storage	and	analysis.	
Currently,	there	are	no	or	few	standards	to	design	or	
compare	databases	on	micro	arrays	results.	However,	
at	investigation	of	the	Microarray	Gene	Expression	Da­
tabase	(MGED)	group,	several	research	groups	tend	to	
define	the	minimal	criteria	required	for	any	publication	
of	results	based	on	microarray	experiments,	and	have	
drawn	up	the	Minimum	Information	About	Microarray	
Experiment	(MIAME).
“AD-HOC” DENSITY ARRAYS
Microarray	technology	constitutes	a	powerful	tool	
for	high­throughput	analysis	of	biological	or	clinical	
specimens.	Technical	advance	combined	to	decreas­
ing	costs	contribute	to	bring	microarrays	accessible,	
commercially	available	whole	genome	arrays	com­
monplace.	Controversially,	beyond	 the	 initial	enthu­
siasm	 that	any	new	 technology	can	 induce	and	 the	
fascination	that	researchers	or	clinicians	have	in	front	
of	thousands	of	genomic	data	from	a	single	sample,	
their	clinical	aptness	 to	become	a	 routine	 tool	start	
just	to	be	demonstrated.	Considerations	about	clinical	
applications	such	as	 tissue	sampling	and	biological	
material	variability	and	data	analysis,	still	present	major	
limitations	for	routine	use	[8].
Consequently,	molecular	profiling	have	been	develo­
ped	using	a	set	of	10	to	200	“ad­hoc”	genes	of	which	
the	pattern	of	alteration	is	the	most	discriminating	for	
the	management	of	 the	disease	[6,	8].	Genotyping,	
real­time	RT­PCR	or	 tissues	arrays	are	adapted	 for	
this	approach	dedicated	to	clinical	validation	of	results	
obtained	by	large	scale	or	whole	genome	screening	
and	to	turn	on	individual	genomic	medicine.
INHERITED (GERM LINE) GENETIC 
PROFILING
Therapy	 is	often	 limited	 to	a	certain	cumulative	
dose.	If	practitioners	could	identify	patients	with	ge­
netic	factors	that	are	associated	with	a	lower	proba­
bility	of	drug	or	beam	therapy	toxicity,	they	would	be	
able	to	administer	higher,	more	effective	doses	to	such	
patients,	and	thereby	increase	the	therapeutic	range	
for	 that	subset	of	 the	patient	population.	Moreover,	
for	prostate	cancer	genetic	polymorphisms	and	par­
ticularly	those	involving	genes	determining	the	steroid	
biosynthesis	 and	metabolism	pathway	 (androgen	
receptor,	5­alpha­reductase	type	 II,	CYP	17,	aroma­
tase,	CYP	3A4,	Cyp1B1,	vitamin	D	receptor	genes)	or	
drug	and	carcinogen	metabolizing	enzymes	 (NAT	1	
and	NAT	2,	CYP2D6,	CYP3A,	CYP1B1,	glutathione­
5­transferase)	or	DNA	 repair	genes	 (ATM,	XRCC1,	
XRCC3,	 XRCC5,	NBS,	MRE11,	 ARE1,	 RAD50)	 or	
oxidative	stress	(SOD2)	or	post	radiotherapy	fibrosis	
(TGF	beta­1)	were	hypothesized	to	be	the	probable	
explanation	for	differences	in	tumor	aggressiveness,	
therapeutic	response	and	adverse	effects	of	treatment	
among	genetic	variability	[9,	10,	11,	12].	Thus,	genomic	
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investigations	of	constitutional	DNA	changes	in	human	
genes	predisposing	to	cancer	may	lead	to	significant	
advances	in	management	of	prostate	cancers	but	need	
also	large	scale	genomic	profiling	[10,	13,	14,	15].
CONCLUSION
It	is	clear	that	genomics	arrays	continue	to	be	ap­
plied	with	success	in	many	relevant	areas	of	research	
and	are	ripe	for	application	to	a	multitude	of	clinical	
problems	especially	in	oncology.	However,	there	are	
substantive	technical	issues	associated	with	the	use	of	
DNA	microarrays	data	that	limit	their	interpretation	and	
consequently	their	implication	in	clinical	practice.	The	
true	challenge	of	the	future	for	clinical	routine	use	of	
DNA	microarrays	will	be	to	determine	if	clinician	need	
genome­wide	gene	alteration	profiling	or	a	limited	and	
relevant	set	of	genomic	data	specifically	designed	for	
dedicated	disease	or	therapeutic	strategy.
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МОЛЕКУЛЯРНЫЕ ОсОбЕННОсти КЛЕтОК РАКА 
ПРЕДстАтЕЛЬНОЙ ЖЕЛЕЗЫ
В обзоре обсуждается целесообразность применения геномных микрочипов для выявления рака предстательной железы. 
Рак является многоэтапным процессом мутаций в ключевых регуляторных генах и эпигенетических изменений, приводящих 
к утрате сбалансированной экспрессии генов. Фундаментальные знания о взаимосвязи между генетической вариабельностью 
опухолевых клеток (молекулярном профиле опухоли) и генетической вариабельностью хозяина (наследуемый геномный 
профиль) позволит выбрать наилучшую стратегию противоопухолевой терапии при низкой токсичности таковой. Изменения 
последовательности гормонсвязывающего домена рецептора андрогена наряду с мутациями некоторых генов определяют 
устойчивость к лучевой терапии и устойчивость или чувствительность к ряду химиопрепаратов. Новые виды терапии 
с использованием моноклональных антител против специфичных внеклеточных связывающих доменов ряда рецепторов 
основаны на данных о молекулярных особенностях новообразований. 
Ключевые слова: рак предстательной железы, микрочип, геномика.
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